ãã°ã€ã³ã§çµç¹ã»å¥çŽäŸ¡æ Œãã芧ãã ããã
ãµã€ãºãéžæããŠãã ãã
衚瀺ã倿Žãã
ãã®ååã«ã€ããŠ
å®éšåŒïŒãã«è¡šèšæ³ïŒ:
C12H21N · xHCl
CASçªå·:
ååé:
179.30 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Storage condition:
OK to freeze, protect from light
ãã¯ãã«ã«ãµãŒãã¹
ãå°ãã®ããšãããã°ãçµéšè±å¯ãªãã¯ãã«ã«ãµãŒãã¹ããŒã ãã客æ§ããµããŒãããŸãã
ãæäŒãããŸãassay
≥98% (HPLC)
Quality Segment
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
H2O: 100 mM
storage temp.
2-8°C
SMILES string
[Cl-].[N+H3]C21CC3(CC(C2)(CC(C1)C3)C)C
InChI
1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H
InChI key
LDDHMLJTFXJGPI-UHFFFAOYSA-N
General description
A very potent, voltage-dependent, rapidly unbinding antagonist (calcium channel blocker) of NMDA receptors (IC50 = 0.8, 0.57, 0.52, and 0.54 µM for GluN2A, B, C, and D, respectively). A popular medicine for treating moderate-to-severe Alzheimerâ²s disease. Frequently used in studying brain functions and disorders involving neurotransmission mediated by NMDA receptors (i.e. learning and memory, cognitive functions, neuroplasticity, Alzheimerâ²s disease, schizophrenia, bipolar depression, obsessive-compulsive disorders, oxidative stress, and excitotoxicity).
Memantine Hydrochloride is a very potent, voltage-dependent, rapidly unbinding antagonist (calcium channel blocker) of NMDA receptors.
Biochem/physiol Actions
Primary Target
NMDA receptors
NMDA receptors
Target IC50: 0.8, 0.57, 0.52, and 0.54 âM for GluN2A, B, C, and D, respectively.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Limapichat, W., et al. 2012. ACS Chem. Neurosci.4, 255.
Anand, A., et al. 2012. Bipolar Dis.14, 64.
Lopes, P., et al. 2013. Brain and Behavior.3, 67.
Howard, R., et al. 2012. New Eng. J. Med.366, 893.
Parsons, G., et al. 1999. Neuropharmacol.38, 735.
Lee, G., et al. 2012. Psychiatry Investig.9, 166.
Anand, A., et al. 2012. Bipolar Dis.14, 64.
Lopes, P., et al. 2013. Brain and Behavior.3, 67.
Howard, R., et al. 2012. New Eng. J. Med.366, 893.
Parsons, G., et al. 1999. Neuropharmacol.38, 735.
Lee, G., et al. 2012. Psychiatry Investig.9, 166.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
ä¿ç®¡åé¡
11 - Combustible Solids
WGK
WGK 3
åŒç«ç¹ (F)
Not applicable
åŒç«ç¹ïŒÂ°CïŒ
Not applicable
ææ°ããŒãžã§ã³ã®ãããããéžæããŠãã ããïŒ
以åãã®è£œåãè³Œå ¥ããã ããããšãããå Žå
ææžã©ã€ãã©ãªã§ãæè¿è³Œå ¥ãã補åã®ææžãæ€çŽ¢ã§ããŸãã